PANACEABIONSEPanacea Biotec Limited· PharmaceuticalsMediumPositive
Announced Tue, 7 Apr · 12:17 IST

Panacea Biotec Limited has informed the Exchange about the receipt of rectified Assessment Order dated 06.04.2026 from the Deputy Commissioner of Income Tax. Under this order, the errors have been corrected, and the Company's tax liability for AY 2015-16 has been determined as Nil.

Regulatory & Legal View source PDF

PANACEABIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+3.4%1-day move
₹322.00
prior close
₹321.45
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0+0.1+0.5+0.4+3.4+0.3+1.3+3.3+7.9+11.7+14.6+25.9+71.7+66.5
Up moveDown movePending
AI summary

Panacea Biotec has received a rectified Assessment Order dated April 6, 2026, from the Deputy Commissioner of Income Tax, New Delhi, for Assessment Year 2015-16. Earlier, on February 27, 2026, the DCIT had raised a tax demand of approximately ₹45.71 crore after disallowing certain expenditures. The company filed a rectification application citing errors such as double addition of disallowances and omission of set-off for brought-forward losses. Following this, the DCIT has corrected these errors and determined the company's tax liability as Nil. The company has confirmed no adverse financial or operational impact is expected from this order.

Likely market impact

This is a significant positive outcome for shareholders — the earlier ₹45.71 crore tax demand has been entirely nullified, removing a major potential financial liability. This should be viewed favorably by the market, as it preserves the company's cash flows and earnings for the relevant period.